The use of adoptive cell therapy for the treatment of SARS-CoV-2 in a patient after allogeneic hematopoietic stem cell transplantation

The COVID-19 pandemic continues to be a major public health threat worldwide. course of this disease in immunocompromised patients is significantly different from that healthy subjects, which associated with the impossibility virus elimination through their own adaptive immune response. Delayed reconstitution after hematopoietic stem cell transplantation (which may take months procedure) increases risk life-threatening infection necessitating search for and application new methods treatment. T lymphocytes are critically important viral control, necessary both direct Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology Ministry Healthcare Russian Federation. patient's parents gave consent use child's data, including photographs, research purposes publications.